學門類別
政大
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- Leadership Imperatives in an AI World
- Vodafone Idea Merger - Unpacking IS Integration Strategies
- Predicting the Future Impacts of AI: McLuhan’s Tetrad Framework
- Snapchat’s Dilemma: Growth or Financial Sustainability
- V21 Landmarks Pvt. Ltd: Scaling Newer Heights in Real Estate Entrepreneurship
- Did I Just Cross the Line and Harass a Colleague?
- Winsol: An Opportunity For Solar Expansion
- Porsche Drive (B): Vehicle Subscription Strategy
- Porsche Drive (A) and (B): Student Spreadsheet
- TNT Assignment: Financial Ratio Code Cracker
-
Raffles Holdings Limited - Valuation of a Divestiture
In 2005, CapitaLand announced the sale of the hotel business under its subsidiary Raffles Holdings Limited for US$1.45 billion. This included the sale of landmark Raffles Hotel as well as 40 other hotels, including the Swissôtel international hotel chain. The case focuses on the financial and the strategic aspects of the sale from the perspective of CapitaLand and includes the following: • What should be an appropriate valuation for Raffles Holdings? • How should the value of intangible assets such as brand name be incorporated? • Was there strategic justification for CapitaLand to pursue a divestiture that would translate into loss of the iconic Raffles Hotel - a national monument of Singapore? -
Cultural Challenges of Integration: Value Creation and Daiichi Sankyo's Indian Acquisition
In the first decade of 2000, major global innovator drug companies were acquiring or collaborating with generic drug companies. Daiichi Sankyo was the first major Japanese Pharmaceutical firm to test this 'hybrid' business model in early 2008 when it acquired a majority share in Ranbaxy, then the largest India-based generic drug company and a global generic drug manufacturer and exporter. At Ranbaxy, the acquisition was followed quickly by several leadership changes. Chairman/ CEO Malvinder Singh, the grandson of Ranbaxy's founder, resigned in May 2009; Atul Sobti who took over as CEO, resigned the following year citing differences with the Japanese company on the running of Ranbaxy. In early 2011, Ranbaxy President and Chief Financial Officer, Omesh Sethi also left the company. On the financial front, the Japanese firm booked a valuation loss of US$3.9 billion from the acquisition in the third quarter of its 2008 financial year and recorded a net loss of US$2.21 billion for that financial year. With the acquisition, Daiichi Sankyo was able to expand the scope of its global business and to lessen the concentration of its assets in Japan from 78.96% to 53.7% in 2011. However, in 2011, the Japanese firm had yet to reap the full benefits of its vision of a value chain based on an integrated hybrid business model. Was a transformational organizational change needed to realize this? The case study examines the cross-cultural challenges of integrating the two businesses as the leadership worked to implement the hybrid business model.